88.51
price down icon0.24%   -0.21
after-market After Hours: 88.51
loading
Blueprint Medicines Corp stock is traded at $88.51, with a volume of 1.29M. It is down -0.24% in the last 24 hours and down -8.35% over the past month. Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.
See More
Previous Close:
$88.72
Open:
$86.82
24h Volume:
1.29M
Relative Volume:
1.41
Market Cap:
$5.49B
Revenue:
$434.41M
Net Income/Loss:
$-128.05M
P/E Ratio:
-41.95
EPS:
-2.11
Net Cash Flow:
$-250.52M
1W Performance:
-7.10%
1M Performance:
-8.35%
6M Performance:
-4.31%
1Y Performance:
-6.69%
1-Day Range:
Value
$85.35
$88.74
1-Week Range:
Value
$85.35
$95.30
52-Week Range:
Value
$80.67
$121.90

Blueprint Medicines Corp Stock (BPMC) Company Profile

Name
Name
Blueprint Medicines Corp
Name
Phone
617-374-7580
Name
Address
45 SIDNEY STREET, CAMBRIDGE, MA
Name
Employee
655
Name
Twitter
@BlueprintMeds
Name
Next Earnings Date
2024-10-30
Name
Latest SEC Filings
Name
BPMC's Discussions on Twitter

Compare BPMC with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
BPMC
Blueprint Medicines Corp
88.51 5.49B 434.41M -128.05M -250.52M -2.11
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.82 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
634.23 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
591.87 36.10B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
270.02 35.03B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
272.17 28.24B 3.81B -644.79M -669.77M -6.24

Blueprint Medicines Corp Stock (BPMC) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-20-25 Resumed Morgan Stanley Equal-Weight
Mar-18-25 Initiated Wolfe Research Outperform
Mar-17-25 Initiated Jefferies Buy
Mar-07-25 Initiated Scotiabank Sector Outperform
Nov-14-24 Initiated JP Morgan Overweight
Oct-24-24 Initiated UBS Neutral
May-14-24 Initiated Stephens Overweight
May-06-24 Upgrade Leerink Partners Underperform → Market Perform
Oct-27-23 Upgrade Oppenheimer Perform → Outperform
Aug-21-23 Reiterated Needham Buy
Jul-31-23 Upgrade Wells Fargo Equal Weight → Overweight
Jun-05-23 Downgrade SVB Securities Market Perform → Underperform
Jan-03-23 Upgrade Wells Fargo Underweight → Equal Weight
Dec-14-22 Initiated Needham Buy
Nov-02-22 Downgrade Oppenheimer Outperform → Perform
Sep-14-22 Initiated Berenberg Buy
Jul-08-22 Initiated Oppenheimer Outperform
Jun-27-22 Initiated Wells Fargo Underweight
Jun-10-22 Downgrade Citigroup Neutral → Sell
Jun-01-22 Upgrade Jefferies Hold → Buy
Mar-01-22 Initiated Citigroup Neutral
Feb-17-22 Downgrade SVB Leerink Outperform → Mkt Perform
Jan-25-22 Upgrade Stifel Hold → Buy
Nov-19-21 Resumed Morgan Stanley Equal-Weight
Sep-30-21 Resumed Stifel Hold
Jun-04-21 Resumed Robert W. Baird Outperform
Mar-31-21 Initiated Credit Suisse Neutral
Dec-03-20 Initiated Stifel Hold
Nov-02-20 Reiterated H.C. Wainwright Buy
Nov-02-20 Downgrade Jefferies Buy → Hold
Oct-30-20 Downgrade Morgan Stanley Overweight → Equal-Weight
Jul-15-20 Reiterated H.C. Wainwright Buy
May-05-20 Initiated Barclays Equal Weight
Mar-17-20 Upgrade BMO Capital Markets Market Perform → Outperform
Jan-28-20 Initiated BMO Capital Markets Market Perform
Jan-27-20 Initiated BMO Capital Markets Market Perform
Nov-06-19 Upgrade Raymond James Outperform → Strong Buy
Oct-22-19 Initiated JMP Securities Mkt Outperform
Oct-03-19 Initiated H.C. Wainwright Buy
Sep-12-19 Upgrade Raymond James Mkt Perform → Outperform
Aug-29-19 Initiated Piper Jaffray Neutral
Aug-15-19 Resumed Raymond James Mkt Perform
Jul-18-19 Initiated Deutsche Bank Buy
May-23-19 Resumed Goldman Buy
Apr-03-19 Initiated Morgan Stanley Overweight
Sep-25-18 Initiated Leerink Partners Outperform
Dec-11-17 Reiterated Goldman Buy
View All

Blueprint Medicines Corp Stock (BPMC) Latest News

pulisher
08:00 AM

Exclusive: Blueprint Medicines Leadership Takes Center Stage at Major Healthcare Conference - Stock Titan

08:00 AM
pulisher
Mar 30, 2025

Is Blueprint Medicines (BPMC) One of the Best Mid Cap Biotech Stocks to Buy? - Insider Monkey

Mar 30, 2025
pulisher
Mar 27, 2025

Blueprint Medicines at H.C. Wainwright Conference: Strategic Pipeline Expansion - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

Blueprint Medicines at H.C. Wainwright Conference: Strategic Pipeline Expansion By Investing.com - Investing.com UK

Mar 27, 2025
pulisher
Mar 26, 2025

Blueprint Medicines COO Christina Rossi sells shares worth $216,075 - Investing.com India

Mar 26, 2025
pulisher
Mar 25, 2025

Is Blueprint Medicines Corporation (BPMC) a Promising Biotech Stock According to Wall Street Analysts - Yahoo Finance

Mar 25, 2025
pulisher
Mar 25, 2025

PNC Financial Services Group Inc. Boosts Stake in Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World

Mar 25, 2025
pulisher
Mar 22, 2025

Proficio Capital Partners LLC Makes New $1.01 Million Investment in Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World

Mar 22, 2025
pulisher
Mar 21, 2025

Blueprint Medicines Co. (NASDAQ:BPMC) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World

Mar 21, 2025
pulisher
Mar 20, 2025

The Analyst Verdict: Blueprint Medicines In The Eyes Of 14 Experts - Benzinga

Mar 20, 2025
pulisher
Mar 20, 2025

Blueprint Medicines (BPMC): Among Stocks Insiders Are Selling In March - Insider Monkey

Mar 20, 2025
pulisher
Mar 20, 2025

Morgan Stanley sets Blueprint Medicines stock at Equalweight, $100 target - Investing.com

Mar 20, 2025
pulisher
Mar 20, 2025

Morgan Stanley sets Blueprint Medicines stock at Equalweight, $100 target By Investing.com - Investing.com UK

Mar 20, 2025
pulisher
Mar 19, 2025

Blueprint Medicines’ SWOT analysis: stock poised for growth amid challenges - Investing.com

Mar 19, 2025
pulisher
Mar 19, 2025

Blueprint Medicines Co. (NASDAQ:BPMC) Shares Sold by Victory Capital Management Inc. - Defense World

Mar 19, 2025
pulisher
Mar 18, 2025

Wolfe Research initiates Blueprint Medicines with Outperform rating - Investing.com

Mar 18, 2025
pulisher
Mar 18, 2025

Blueprint Medicines (NASDAQ:BPMC) Now Covered by Jefferies Financial Group - Defense World

Mar 18, 2025
pulisher
Mar 17, 2025

This Blueprint Medicines Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga

Mar 17, 2025
pulisher
Mar 17, 2025

241,966 Shares in Blueprint Medicines Co. (NASDAQ:BPMC) Purchased by Raymond James Financial Inc. - Defense World

Mar 17, 2025
pulisher
Mar 17, 2025

Blueprint Medicines initiated with a Buy at Jefferies - TipRanks

Mar 17, 2025
pulisher
Mar 17, 2025

Jefferies sets Blueprint Medicines stock Buy rating, $135 target - Investing.com

Mar 17, 2025
pulisher
Mar 17, 2025

Jefferies sets Blueprint Medicines stock Buy rating, $135 target By Investing.com - Investing.com Philippines

Mar 17, 2025
pulisher
Mar 16, 2025

Blueprint Medicines (NASDAQ:BPMC) Shares Down 1.6% – Here’s Why - Defense World

Mar 16, 2025
pulisher
Mar 15, 2025

Blueprint Medicines director Jeffrey Albers sells $658,500 in stock By Investing.com - Investing.com Australia

Mar 15, 2025
pulisher
Mar 15, 2025

Steward Partners Investment Advisory LLC Lowers Position in Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World

Mar 15, 2025
pulisher
Mar 15, 2025

Blueprint Medicines director Jeffrey Albers sells $658,500 in stock - Investing.com India

Mar 15, 2025
pulisher
Mar 14, 2025

Charles Schwab Investment Management Inc. Purchases 7,165 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World

Mar 14, 2025
pulisher
Mar 13, 2025

Blueprint Medicines’ SWOT analysis: strong Ayvakit sales drive stock outlook By Investing.com - Investing.com South Africa

Mar 13, 2025
pulisher
Mar 13, 2025

Blueprint Medicines’ SWOT analysis: strong Ayvakit sales drive stock outlook - Investing.com

Mar 13, 2025
pulisher
Mar 10, 2025

US Bancorp DE Sells 1,988 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World

Mar 10, 2025
pulisher
Mar 10, 2025

Blueprint Medicines Co. (NASDAQ:BPMC) Stock Holdings Lifted by Bank of New York Mellon Corp - Defense World

Mar 10, 2025
pulisher
Mar 09, 2025

Blueprint Medicines (NASDAQ:BPMC) Coverage Initiated at Scotiabank - Defense World

Mar 09, 2025
pulisher
Mar 08, 2025

Blueprint Medicines CFO sells shares worth $469,219 By Investing.com - Investing.com South Africa

Mar 08, 2025
pulisher
Mar 08, 2025

Proficio Capital Partners LLC Purchases Shares of 11,600 Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World

Mar 08, 2025
pulisher
Mar 08, 2025

Blueprint Medicines CEO sells $1.43 million in stock By Investing.com - Investing.com Australia

Mar 08, 2025
pulisher
Mar 08, 2025

Zacks Research Has Positive Outlook for BPMC Q1 Earnings - Defense World

Mar 08, 2025
pulisher
Mar 07, 2025

Blueprint Medicines Stock: Executives Sell Shares Amid Growth - sharewise

Mar 07, 2025
pulisher
Mar 07, 2025

Blueprint Medicines CMO Hewes L. Becker sells $890k in stock - Investing.com Canada

Mar 07, 2025
pulisher
Mar 07, 2025

Blueprint Medicines EVP sells shares worth $467,265 By Investing.com - Investing.com South Africa

Mar 07, 2025
pulisher
Mar 07, 2025

Blueprint Medicines CEO sells $1.43 million in stock - Investing.com

Mar 07, 2025
pulisher
Mar 07, 2025

Blueprint Medicines EVP sells shares worth $467,265 - Investing.com India

Mar 07, 2025
pulisher
Mar 07, 2025

Blueprint Medicines chief commercial officer Lee Philina sells $331,490 in stock - Investing.com

Mar 07, 2025
pulisher
Mar 07, 2025

Blueprint Medicines CFO sells shares worth $469,219 - Investing.com

Mar 07, 2025
pulisher
Mar 07, 2025

Blueprint Medicines Executives Sell Shares to Cover Tax Obligations - TradingView

Mar 07, 2025
pulisher
Mar 07, 2025

Upward Trajectory: Blueprint Medicines Corp (BPMC) Posts a Slidee, Closing at 88.54 - The Dwinnex

Mar 07, 2025
pulisher
Mar 07, 2025

Scotiabank sets Blueprint Medicines stock target at $150 - Investing.com

Mar 07, 2025
pulisher
Mar 07, 2025

Blueprint Medicines Corp. to Host Earnings Call - ACCESS Newswire

Mar 07, 2025
pulisher
Mar 07, 2025

Truist Financial Corp Makes New Investment in Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World

Mar 07, 2025

Blueprint Medicines Corp Stock (BPMC) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$70.69
price down icon 1.05%
$76.29
price down icon 2.18%
$31.13
price down icon 0.77%
$19.29
price down icon 5.07%
$91.06
price down icon 4.10%
biotechnology ONC
$272.17
price up icon 1.79%
Cap:     |  Volume (24h):